

FREQUENTLY ASKED QUESTIONS ABOUT NAVIGATING YOUR INSURANCE BENEFITS TO ACCESS RADICAVA® (EDARAVONE)

The following are answers to frequently asked questions regarding the benefits investigation process and scheduling infusions in order to access RADICAVA® (edaravone) treatment

How do I obtain RADICAVA?

RADICAVA is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) and indicated for all adult patients with amyotrophic lateral sclerosis (ALS). The benefits investigation and product access process to obtain RADICAVA is initiated by your healthcare provider (HCP) and facilitated through Searchlight Support®, which provides assistance for people who are prescribed RADICAVA. Key steps in the process include:

- 1) **TREATMENT DECISION:** Patient visits HCP, who determines whether RADICAVA is an appropriate treatment for patient.
- 2) **BENEFITS VERIFICATION:** Before beginning treatment, the patient's insurance coverage must be confirmed:
 - a. HCP submits Benefits Investigation and Enrollment Form to connect patient to Searchlight Support. Forms (available at RADICAVA.com/HCP) can be submitted by the HCP online through a secure HCP portal, faxed or mailed.
 - b. Searchlight Support conducts rapid benefits investigation to confirm patient insurance coverage and assigns a patient ID.
 - c. By using Searchlight Support, and the Care Coordinators, an HCP's office should be able to identify a location for infusion service based on a patient's insurance benefits and geographical proximity (ALS center, home infusion, physician's office, free-standing infusion center or hospital outpatient department).
 - d. Care Coordinator contacts patient to explain benefits and discuss co-pay support options.
- 3) **SCHEDULING INFUSIONS:** Patient or HCP office contacts infusion site or home infusion provider to schedule the first cycle of treatment.
- 4) **RADICAVA ORDERED:** Site of care submits order form with patient ID to Searchlight Support to obtain RADICAVA for scheduled treatment. Searchlight Support facilitates



Mitsubishi Tanabe Pharma America



RADICAVA, the RADICAVA logo and the Mitsubishi Tanabe Pharma America logo are registered trademarks of Mitsubishi Tanabe Pharma Corporation.

Searchlight Support is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

© 2018 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

RADICAVA shipment from distributor to infusion site.

For more information on the benefits investigation process call 1-844-SRCHLGT (1-844-772-4548). Visit RADICAVA.com for more information and sign up to receive email updates about RADICAVA.

How does the Searchlight Support program work?

Searchlight Support provides assistance for people with ALS who receive RADICAVA.

Searchlight Support can provide:

- **Care Coordinator:** Every person who enrolls will have access to a dedicated, personal Care Coordinator who will help them investigate their insurance benefits.
- **Patient Assistance Program:** We know every day matters for people with ALS. So, we created a program in which eligible uninsured patients may receive RADICAVA at no charge from Mitsubishi Tanabe Pharma America, Inc. (MTPA) for up to two years. How the Patient Assistance Program works:
 - You and your HCP complete the Benefit Investigation and Enrollment Form and submit to Searchlight Support with all required documentation.
 - If you meet the Patient Assistance Program requirements, the program will cover your RADICAVA medication as prescribed by your HCP at no charge for one year.*
 - You must reconfirm your eligibility for continued participation in the program after your initial 12-month eligibility period by providing required financial documentation.
 - If you continue to meet the program requirements, you may be able to receive your medication at no charge for an additional 12 months.

For more information, call 1-844-SRCHLGT or 1-844-772-4548. Patients prescribed RADICAVA should check eligibility requirements for each aspect of our Patient Assistance Program, as restrictions apply.

**Only product provided at no charge. The Patient Assistance Program covers only the cost of RADICAVA and not the cost of any infusion services or healthcare provider visits, which are the sole responsibility of the patient.*



Mitsubishi Tanabe Pharma America



RADICAVA, the RADICAVA logo and the Mitsubishi Tanabe Pharma America logo are registered trademarks of Mitsubishi Tanabe Pharma Corporation.

Searchlight Support is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

© 2018 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

What are the important things to know about scheduling my treatment?

If your HCP prescribes RADICAVA for you, a dedicated Care Coordinator is ready to help you find an infusion site of care. You or your HCP can contact the infusion site or home infusion provider to schedule the first cycle of treatment. Consider transportation to and from your appointments.

Is RADICAVA shipped directly to me? What do I need to know about storing it?

If you plan to receive RADICAVA at an infusion center, the medicine will be shipped directly to your provider. RADICAVA should be stored at room temperature and should be administered within 24 hours of opening the package.¹

Important Safety Information for RADICAVA (edaravone injection)

IMPORTANT SAFETY INFORMATION

Before you receive RADICAVA, tell your healthcare provider about all of your medical conditions, including if you:

- have asthma.
- are allergic to other medicines.
- are pregnant or plan to become pregnant. It is not known if RADICAVA will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if RADICAVA passes into your breastmilk. You and your healthcare provider should decide if you will receive RADICAVA or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of RADICAVA?

- RADICAVA may cause serious side effects including hypersensitivity (allergic) reactions and sulfite allergic reactions.
- Hypersensitivity reactions have happened in people receiving RADICAVA and can happen after your infusion is finished.
- RADICAVA contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe



Mitsubishi Tanabe Pharma America



RADICAVA, the RADICAVA logo and the Mitsubishi Tanabe Pharma America logo are registered trademarks of Mitsubishi Tanabe Pharma Corporation.

Searchlight Support is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

© 2018 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.

asthma episodes in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma.

- Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: hives; swelling of the lips, tongue, or face; fainting; breathing problems; wheezing; trouble swallowing; dizziness; itching; or an asthma attack (in people with asthma).
- Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects.

The most common side effects of RADICAVA include bruising (contusion), problems walking (gait disturbance), and headache.

These are not all the possible side effects of RADICAVA. Call your healthcare provider for medical advice about side effects. You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

For medical questions, call 1-888-292-0058 or to find more information, including full Prescribing Information, please visit RADICAVA.com.

¹ RADICAVA® U.S. Prescribing Information. May 2017.



Mitsubishi Tanabe Pharma America



RADICAVA, the RADICAVA logo and the Mitsubishi Tanabe Pharma America logo are registered trademarks of Mitsubishi Tanabe Pharma Corporation.

Searchlight Support is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

© 2018 Mitsubishi Tanabe Pharma America, Inc. All rights reserved.